Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
If direct-to-consumer channels prove successful, we may see further disintermediation of traditional pharmacy benefit models, particularly for high-demand therapies such as GLP-1s
As forecasts predict multi-billion-dollar revenues, the landscape of chronic disease management, particularly obesity, is undergoing a profound shift
For example, some insurance plans, including Medicare, do not cover weight loss medications like Saxenda at all
However, there was a problem : GLP-1 quickly disappears from the human body, positing difficulties in drug development
US$ 21.97
US$ 28.87
US$ 28.29
US$ 22.37
